Sylvie Chabaud

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 145 publications

Development of an externally controlled trial from a single-arm study to assess first-line immunochemotherapy in advanced large cell neuroendocrine lung carcinomas: a study protocol from the FIRST-NEC GFPC 01-2022 trial.

Development of an externally controlled trial from a single-arm study to assess first-line immunochemotherapy in advanced large cell neuroendocrine lung carcinomas: a study protocol from the FIRST-NEC GFPC 01-2022 trial.

Journal: BMJ open

Published: July 29, 2026

Response to Yu, Wang and Ge.

Response to Yu, Wang and Ge.

Journal: Journal of the National Cancer Institute

Published: June 15, 2026

Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.

Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 11, 2026

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

Journal: European urology

Published: May 11, 2026

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 19, 2026

COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study.

COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 19, 2025

Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group.

Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 12, 2025

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis.

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis.

Journal: Lancet (London, England)

Published: October 01, 2025

Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03.

Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03.

Journal: Breast (Edinburgh, Scotland)

Published: August 26, 2025

Reply to: Critical evaluation of the ProfiLER-02 study design and outcomes.

Reply to: Critical evaluation of the ProfiLER-02 study design and outcomes.

Journal: Nature medicine

Published: August 12, 2025

Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.

Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.

Journal: European urology

Published: July 01, 2025

SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers.

SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers.

Journal: Therapeutic advances in medical oncology

Published: June 06, 2025

Showing 1-12 of 145

Last Updated: 09/26/2026